With $130M, Protego pushes forward a new type of amyloidosis drug
The startup’s lead prospect stabilizes abnormal proteins in patients with amyloid “light chain” amyloidosis, an approach that could represent a step forward compared to current therapies.
In AL amyloidosis, plasma cells errantly make abnormal antibody parts known as “light chains,” which then misfold, clump up in tissues and damage organs. While there are certain options available, like a stem cell transplant, or a cocktail of cancer chemotherapies and the drug Darzalex, they each have limitations.
Pfizer reported an ATTR sales decline in the US. Should newer market entrants Alnylam and BridgeBio worry?
The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion market, may have just revealed the first indication of a slowdown.
For the three months ended in September, Pfizer reported a 1% sales decline year over year for its family of tafamidis products in the U.S. The $948 million haul also marked a 4% sequential decrease from the prior quarter that ended in June.
ATTRwt Research Study: Days alive and out of hospital in patients with ATTRwt
While overall survival has been extensively studied in amyloidosis, less attention has been given to patient-centered measures that integrate morbidity and mortality. Days Alive and Out of Hospital (DAOH) is an emerging metric that captures both aspects and has potential utility in the evaluation of disease impact.To describe DAOH in patients with wild-type transthyretin amyloidosis (ATTRwt) and explore factors associated with DAOH.Retrospective cohort study used the Institutional Registry of Amyloidosis database of the Hospital Italiano de Buenos Aires (2015–2023).
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
The purpose of this study is to: - Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events - Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death - Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life.
For more information:NCT07052903
Alnylam gains EC approval for Amvuttra in ATTR amyloidosis
Alnylam Pharmaceuticals has secured European Commission (EC) approval for Amvuttra (vutrisiran) to treat transthyretin (ATTR) amyloidosis with cardiomyopathy.
Amvuttra is an RNAi therapeutic that delivers rapid knockdown of variant and wild type transthyretin (TTR), addressing the underlying cause of ATTR amyloidosis.
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of its RNAi therapeutic vutrisiran for the treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
VA Expands Access to Amyloidosis Treatment
For years, veterans with polyneuropathy caused by amyloidosis have faced barriers to receiving the right treatment. The Veterans’ Administration formulary required patients to try medications intended for cardiomyopathy before they could access therapy indicated for polyneuropathy.